PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Clinical Trials
5.0k
Trial Phases
6 Phases
Drug Approvals
17
Drug Approvals
Rimegepant Sulfate Orally Disintegrating Tablets
- Product Name
- 乐泰可
- Approval Number
- 国药准字HJ20240004
- Approval Date
- Jan 23, 2024
Ritlecitinib Tosylate Capsules
- Product Name
- 乐复诺
- Approval Number
- 国药准字HJ20230118
- Approval Date
- Oct 18, 2023
- Prev
- 1
- 2
- Next
Clinical Trials
Distribution across different clinical trial phases (3897 trials with phase data)• Click on a phase to view related trials
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2025-07-14
- Last Posted Date
- 2025-07-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 400
- Registration Number
- NCT07062965
A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.
- Conditions
- Severe Alopecia Areata
- Interventions
- Drug: Ritlecitinib higher doseDrug: Ritlecitinib lower dose
- First Posted Date
- 2025-06-19
- Last Posted Date
- 2025-06-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 140
- Registration Number
- NCT07029828
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
- Conditions
- Metastatic Castration Sensitive Prostate Cancer (mCSPC)Hormone Sensitive Prostate CancerProstate CancerCancer of the Prostate
- Interventions
- First Posted Date
- 2025-06-19
- Last Posted Date
- 2025-07-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1000
- Registration Number
- NCT07028853
- Locations
- 🇺🇸
Arizona Urology Specialists (AUS)-Professional Park, Tucson, Arizona, United States
🇺🇸Arizona Urology Specialist, Tucson, Arizona, United States
🇨🇳Nantong Tumor Hospital, Nantong, Jiangsu, China
A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata
- Conditions
- Severe Alopecia Areata
- Interventions
- Drug: Ritlecitinib higher doseDrug: Ritlecitinib lower doseDrug: Placebo
- First Posted Date
- 2025-06-19
- Last Posted Date
- 2025-06-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 225
- Registration Number
- NCT07029711
A Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant
- First Posted Date
- 2025-06-15
- Last Posted Date
- 2025-07-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 100
- Registration Number
- NCT07023081
- Locations
- 🇨🇳
Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention, Nanning, Guangxi, China
🇨🇳Wuming District Center for Disease Control and Prevention, Chengxiang, Nanning, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 635
- Next
News
Oxford BioDynamics' EpiSwitch Biomarkers Show Promise in Pfizer Bladder Cancer Trial
Oxford BioDynamics' EpiSwitch blood-based biomarkers demonstrated strong correlation with immune profiles of patient tumors in Pfizer's JAVELIN Bladder 100 trial involving 496 bladder cancer patients.
Uniquity Bio Appoints Will Kane as CEO to Lead Anti-TSLP Therapy Through Phase III Development
Uniquity Bio has appointed Will Kane as President and CEO to advance solrikitug, a monoclonal antibody targeting TSLP, through completion of three Phase II trials and preparation for Phase III development.
ViiV Healthcare Expands Generic License for Long-Acting HIV Treatment to 133 Countries
ViiV Healthcare has expanded its voluntary licensing agreement with the Medicines Patent Pool to allow generic production of cabotegravir for HIV treatment in 133 countries, including all low-income and Sub-Saharan African nations.
Ascentage Pharma Raises $192M in Oversubscribed Share Placement to Advance Cancer Pipeline
Ascentage Pharma completed a $192.3 million share placement that was oversubscribed by eight times, demonstrating strong investor confidence in the company's cancer-focused pipeline.
Pfizer Receives CDSCO Approval for Phase III RSV Vaccine Trial in India with Conditional Requirements
Pfizer's Respiratory Syncytial Virus Prefusion F Subunit Vaccine (RSVPref) received approval from India's CDSCO expert panel to conduct Phase III clinical trials following a June 24, 2025 review meeting.
Centivax Secures $45 Million Series A to Advance Universal Flu Vaccine into Phase I Clinical Trial
Centivax raised an oversubscribed $45 million Series A round led by Future Ventures to advance its universal flu vaccine through Phase I clinical trials beginning within eight months.
STAMPEDE Trial Shows Metformin Improves Metabolic Health in Metastatic Prostate Cancer Patients Despite No Survival Benefit
The STAMPEDE trial found that adding metformin to standard care for 1,874 non-diabetic men with metastatic prostate cancer did not significantly improve overall survival (HR 0.91, 95% CI: 0.80-1.03, P = 0.15).
ViiV Healthcare Presents Real-World Data on Long-Acting HIV Treatments at IAS 2025
ViiV Healthcare presented extensive real-world data at IAS 2025 demonstrating the effectiveness, safety, and tolerability of its long-acting injectable HIV treatments, including cabotegravir + rilpivirine LA for treatment and cabotegravir LA for prevention.
Taiho's Pizuglanstat Fails to Meet Primary Endpoint in Phase III Duchenne Muscular Dystrophy Trial
Taiho Pharmaceutical's pizuglanstat (TAS-205) failed to demonstrate significant improvement in time to rise from floor compared to placebo in the Phase III REACH-DMD study.
Ascentage Pharma Strengthens Leadership Team with New CFO and Senior VP Appointments
Ascentage Pharma appointed Dr. Veet Misra as Chief Financial Officer and Eric Huang as Senior Vice President of Global Corporate Development and Finance to support the company's global expansion strategy.